tetano
Editor, Senior Moderator
Life (Basel)
. 2021 Feb 21;11(2):167.
doi: 10.3390/life11020167.
Post-Infectious Guillain-Barr? Syndrome Related to SARS-CoV-2 Infection: A Systematic Review
Pasquale Sansone[SUP] 1 [/SUP], Luca Gregorio Giaccari[SUP] 1 [/SUP], Caterina Aurilio[SUP] 1 [/SUP], Francesco Coppolino[SUP] 1 [/SUP], Valentina Esposito[SUP] 1 [/SUP], Marco Fiore[SUP] 2 [/SUP], Antonella Paladini[SUP] 3 [/SUP], Maria Beatrice Passavanti[SUP] 1 [/SUP], Vincenzo Pota[SUP] 1 [/SUP], Maria Caterina Pace[SUP] 1 [/SUP]
Affiliations
Abstract
Background. Guillain-Barr? syndrome (GBS) is the most common cause of flaccid paralysis, with about 100,000 people developing the disorder every year worldwide. Recently, the incidence of GBS has increased during the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) epidemics. We reviewed the literature to give a comprehensive overview of the demographic characteristics, clinical features, diagnostic investigations, and outcome of SARS-CoV-2-related GBS patients. Methods. Embase, MEDLINE, Google Scholar, and Cochrane Central Trials Register were systematically searched on 24 September 2020 for studies reporting on GBS secondary to COVID-19. Results. We identified 63 articles; we included 32 studies in our review. A total of 41 GBS cases with a confirmed or probable COVID-19 infection were reported: 26 of them were single case reports and 6 case series. Published studies on SARS-CoV-2-related GBS typically report a classic sensorimotor type of GBS often with a demyelinating electrophysiological subtype. Miller Fisher syndrome was reported in a quarter of the cases. In 78.1% of the cases, the response to immunomodulating therapy is favourable. The disease course is frequently severe and about one-third of the patients with SARS-CoV-2-associated GBS requires mechanical ventilation and Intensive Care Unit (ICU) admission. Rarely the outcome is poor or even fatal (10.8% of the cases). Conclusion. Clinical presentation, course, response to treatment, and outcome are similar in SARS-CoV-2-associated GBS and GBS due to other triggers.
Keywords: COVID-19; Guillain-Barr? syndrome; Miller Fisher syndrome; SARS-CoV-2; severe acute respiratory syndrome coronavirus-2.
. 2021 Feb 21;11(2):167.
doi: 10.3390/life11020167.
Post-Infectious Guillain-Barr? Syndrome Related to SARS-CoV-2 Infection: A Systematic Review
Pasquale Sansone[SUP] 1 [/SUP], Luca Gregorio Giaccari[SUP] 1 [/SUP], Caterina Aurilio[SUP] 1 [/SUP], Francesco Coppolino[SUP] 1 [/SUP], Valentina Esposito[SUP] 1 [/SUP], Marco Fiore[SUP] 2 [/SUP], Antonella Paladini[SUP] 3 [/SUP], Maria Beatrice Passavanti[SUP] 1 [/SUP], Vincenzo Pota[SUP] 1 [/SUP], Maria Caterina Pace[SUP] 1 [/SUP]
Affiliations
- PMID: 33670000
- DOI: 10.3390/life11020167
Abstract
Background. Guillain-Barr? syndrome (GBS) is the most common cause of flaccid paralysis, with about 100,000 people developing the disorder every year worldwide. Recently, the incidence of GBS has increased during the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) epidemics. We reviewed the literature to give a comprehensive overview of the demographic characteristics, clinical features, diagnostic investigations, and outcome of SARS-CoV-2-related GBS patients. Methods. Embase, MEDLINE, Google Scholar, and Cochrane Central Trials Register were systematically searched on 24 September 2020 for studies reporting on GBS secondary to COVID-19. Results. We identified 63 articles; we included 32 studies in our review. A total of 41 GBS cases with a confirmed or probable COVID-19 infection were reported: 26 of them were single case reports and 6 case series. Published studies on SARS-CoV-2-related GBS typically report a classic sensorimotor type of GBS often with a demyelinating electrophysiological subtype. Miller Fisher syndrome was reported in a quarter of the cases. In 78.1% of the cases, the response to immunomodulating therapy is favourable. The disease course is frequently severe and about one-third of the patients with SARS-CoV-2-associated GBS requires mechanical ventilation and Intensive Care Unit (ICU) admission. Rarely the outcome is poor or even fatal (10.8% of the cases). Conclusion. Clinical presentation, course, response to treatment, and outcome are similar in SARS-CoV-2-associated GBS and GBS due to other triggers.
Keywords: COVID-19; Guillain-Barr? syndrome; Miller Fisher syndrome; SARS-CoV-2; severe acute respiratory syndrome coronavirus-2.